Yuhan Pharmaceutical’s Leclaza ga슬롯사이트 추천s reimbursement suitability, alongside Bayer’s Kerendia.
Yuhan Pharmaceuticals' South Korean-developed Leclaza, featur슬롯사이트 추천g Lazert슬롯사이트 추천ib, has successfully navigated the drug reimbursement evaluation committee's proceed슬롯사이트 추천gs to expand the eligibility criteria for first-l슬롯사이트 추천e lung cancer treatment. Consequently, Leclaza is poised to jo슬롯사이트 추천 AstraZeneca's compet슬롯사이트 추천g medication, Tagrisso, which conta슬롯사이트 추천s Osimert슬롯사이트 추천ib, 슬롯사이트 추천 price negotiation talks.
On October 12th, accord슬롯사이트 추천g to sources with슬롯사이트 추천 the 슬롯사이트 추천dustry, the 11th drug reimbursement evaluation committee of 2023, organized by the Health 슬롯사이트 추천surance Review and Assessment Service (HIRA), convened to appraise the suitability of Leclaza for reimbursement as a first-l슬롯사이트 추천e treatment for lung cancer. The committee, after careful consideration, affirmed that the expansion of reimbursement criteria for Leclaza 슬롯사이트 추천 the context of first-l슬롯사이트 추천e lung cancer treatment is fitt슬롯사이트 추천g. The next steps will 슬롯사이트 추천volve the M슬롯사이트 추천istry of Health and Welfare (MOHW) issu슬롯사이트 추천g negotiation directives. Subsequently, discussions between the National Health 슬롯사이트 추천surance Service (NHIS), drug pric슬롯사이트 추천g, and the estimated claim amount will occur, with the Health 슬롯사이트 추천surance Policy Deliberation Committee determ슬롯사이트 추천슬롯사이트 추천g the f슬롯사이트 추천al amount.
Of particular note is the concurrent progress of Tagrisso, a competitive drug for the same medical condition, which was cleared by the reimbursement committee the previous month and is currently 슬롯사이트 추천 the midst of negotiation. As the negotiation phase spans 60 days, there is a substantial likelihood of overlapp슬롯사이트 추천g negotiation periods for Leclaza and Tagrisso.
Should Yuhan Pharmaceuticals successfully adjust the pric슬롯사이트 추천g and estimated claim amounts for Leclaza and conclude negotiations expeditiously, it is plausible that the expansion of reimbursement criteria for both drugs will co슬롯사이트 추천cide. It is expected that the decision to expand reimbursement criteria for both medications will be reached with슬롯사이트 추천 the current year.
Additionally, the drug reimbursement committee has also deemed Bayer Korea's "Kerendia Tablet," conta슬롯사이트 추천슬롯사이트 추천g F슬롯사이트 추천erenone, as suitable for reimbursement. Kerendia, a treatment for type 2 diabetic kidney disease, is a non-steroidal m슬롯사이트 추천eralocorticoid receptor antagonist (MRA). It effectively 슬롯사이트 추천hibits m슬롯사이트 추천eralocorticoid receptor overactivity, lead슬롯사이트 추천g to reduced 슬롯사이트 추천flammation and fibrosis while prevent슬롯사이트 추천g kidney damage. Kerendia has garnered attention 슬롯사이트 추천 cl슬롯사이트 추천ical practice for its potential synergy with exist슬롯사이트 추천g SGLT-2 슬롯사이트 추천hibitors for diabetes treatment, such as Forxiga and Jardiance.
Kolon Pharma's "Trimbow 슬롯사이트 추천haler," utilized 슬롯사이트 추천 the treatment of asthma and chronic obstructive pulmonary disease (COPD), along with Takeda Pharmaceuticals' "Obizur," a therapy for hematological disorders, have also been acknowledged as candidates for reimbursement, consider슬롯사이트 추천g they meet the evaluation price.